ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Insider Sells $241,800.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insider Christopher Mutz sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider now owns 107,317 shares in the company, valued at approximately $6,487,312.65. This represents a 3.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $59.99 on Friday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a fifty day simple moving average of $66.91 and a 200 day simple moving average of $60.77. The company has a market cap of $1.31 billion, a P/E ratio of -109.07 and a beta of 0.56. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. The business had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s quarterly revenue was up 43.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.82 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently modified their holdings of ANIP. Hohimer Wealth Management LLC boosted its holdings in ANI Pharmaceuticals by 5.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company’s stock valued at $334,000 after purchasing an additional 247 shares during the period. Exchange Traded Concepts LLC boosted its holdings in ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after purchasing an additional 310 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock valued at $582,000 after purchasing an additional 364 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after purchasing an additional 412 shares during the period. Finally, Natixis Advisors LLC boosted its holdings in ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock valued at $1,028,000 after purchasing an additional 417 shares during the period. 76.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ANIP. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 24th. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research note on Monday, April 21st. Guggenheim restated a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a “buy” rating and a $80.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $80.13.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.